Denosumab

Denosumab is a human monoclonal antibody that binds Receptor Activator of Nuclear factor Kappa β Ligand (RANKL), a cytokine and member of the tumor necrosis factor superfamily. This prevents interaction between RANKL and the RANK receptor on osteoclasts, inhibiting their maturation, function and survival. Consequentially, bone resorption is inhibited. Bisphosphonates also inhibit osteoclast function (via a different mechanism) and thereby have similar effects. Although denosumab and bisphosphonates share indications and undesirable effects, the latter drugs are significantly less expensive.

Source: Journal of Pain and Symptom Management - June 1, 2018 Category: Palliative Care Authors: Andrew Wilcock, Sarah Charlesworth, Claire Stark Toller, Rahul Girish, Mary Mihalyo, Paul Howard Source Type: research